Clinical Trial Update: Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) [Phase 3]

View source ↗

Summary

Phase 3 trial update on efficacy, immunogenicity, and safety of V503 in Chinese women aged 20-45 with papillomavirus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillomavirus Infections

Drugs mentioned

• V503

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING